Sanjay Pancholi, DO
Internal Medicine · Rock Island, ILNPI 1780894816
Payments from drug & device makers
Across 75 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$291
- AbbVie$239
- Pfizer$172
- Bayer$140
- E.r. Squibb & Sons, L.L.C.$89
- Amgen$77
- plus $467 from 16 others
What the payments were for
- Food & beverage$1,476100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $291 |
| AbbVie(2 entities) | 9 | $239 |
| Pfizer | 10 | $172 |
| Bayer | 7 | $140 |
| E.r. Squibb & Sons, L.L.C. | 5 | $89 |
| Amgen | 4 | $77 |
| GSK | 4 | $72 |
| Boehringer Ingelheim | 4 | $66 |
| Astellas Pharma US Inc | 3 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| AstraZeneca | 2 | $30 |
| Dexcom, Inc. | 2 | $27 |
| Lilly USA, LLC | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$110
How this compares
$1,476 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 168 | $216,206 |
| EliquisApixaban | 150 | $136,423 |
| JanuviaSitagliptin Phosphate | 43 | $67,671 |
| TradjentaLinagliptin | 46 | $42,137 |
| RexultiBrexpiprazole | 22 | $37,352 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $35,171 |
| TrulicityDulaglutide | 27 | $34,075 |
| OzempicSemaglutide | 30 | $33,926 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $18,212 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $13,440 |
| MyrbetriqMirabegron | 27 | $13,128 |
| Spiriva RespimatTiotropium Bromide | 14 | $12,428 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,796 |
| FarxigaDapagliflozin Propanediol | 11 | $10,547 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $66 | $270,771228 claims |
| PfizerEliquis | $172 | $136,423150 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $72 | $77,62093 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $33 | $37,35222 claims |
| Lilly USA, LLCTrulicity | $23 | $34,07527 claims |
| Novo NordiskOzempic | $291 | $33,92630 claims |
| AstraZenecaFarxiga, Symbicort | $30 | $19,66337 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $13,12827 claims |
| AbbVieLumigan | $239 | $3,14512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Rock Island
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.